Atlas market file · Equity · Asia-Pacific
Chengdu Olymvax Biopharmaceuticals Inc. Class A688319
- Last close
- 29.05
- Change
- +1.36%
- 96-bar range
- 20.41 – 44.9
- As of
- 12 Aug 2026
Chengdu Olymvax Biopharmaceuticals Inc. Class A is a healthcare or life-sciences issuer listed as 688319 on SSE. Use this page to check the price chart, company context, source-backed updates, risks and evidence before opening the full Atlas research file.
- Identity
- SSE symbol identity
- Chart rail
- TradingView
- File state
- Public profile
688319
Equity · evidence first
Static Daily candlestick snapshot from the approved cache, drawn on a labelled price axis: green bodies closed up, red closed down, wicks span each bar's high-to-low range. The live TradingView link stays available; the public profile never embeds a widget that can render the wrong symbol.
▮ up candle ▮ down candle
Weekly outlook: the last 104 weekly closes (+228.25% over the window).
Source rail: Yahoo Finance chart API (688319.SS). This dated snapshot is the crawlable Atlas reference.
Live market viewTradingView · provider feed Open view ->
Open the attributed TradingView market view for 688319. The dated Atlas snapshot above remains the crawlable reference; exchange data in this panel may be live or delayed as labelled by TradingView.
688319 public profile
Healthcare or life-sciences issuer. Chengdu Olymvax Biopharmaceuticals Inc. Class A is connected to current market context, cited company sources and its retained research file.
Chengdu Olymvax Biopharmaceuticals Inc. Class A trades as 688319 on SSE. Chengdu Olymvax Biopharmaceuticals Inc. Class A (688319) has a latest verified close of 29.05, up 1.36%, dated 12 Aug 2026.
Open the chart, inspect attributed company evidence and continue into the fuller research file without losing this market context. Atlas files 688319 under Healthcare & Medicine Stocks for browsing.
688319 technical readout
Directional bias down. Wilder ADX and ATR computed from Atlas approved daily OHLC through 2026-07-29. Indicators are descriptive statistics, not investment advice.
Open an Atlas research path on 688319
FreedomCore Atlas can expand this public profile into source-led research files with company snapshots, valuation context, filings and segment detail, source packs, and equity briefs. Each path keeps the underlying public sources visible.
Open Atlas workstation ->Keep 688319 research in your Atlas archive
Free Atlas includes the public profile and one owned welcome research artifact after account setup. Atlas Pro adds up to 25 custom research runs a day, a 500-symbol watchlist, saved report versions, and eligible PDF, CSV, and email artifacts. Evidence holds still apply and never become an unverified download. £12/month founding price, locked for life. Research only; not investment advice.
Checking Atlas access...
688319 FAQ
What is Chengdu Olymvax Biopharmaceuticals Inc. Class A (688319)?Chengdu Olymvax Biopharmaceuticals Inc. Class A (688319) has a latest verified close of 29.05, up 1.36%, dated 12 Aug 2026. Use this page to check the price chart,...
Chengdu Olymvax Biopharmaceuticals Inc. Class A (688319) has a latest verified close of 29.05, up 1.36%, dated 12 Aug 2026. Use this page to check the price chart, company context, source-backed updates, risks and evidence before opening the full Atlas research file.
What does Atlas show for 688319?Chengdu Olymvax Biopharmaceuticals Inc. Class A (688319) has a latest verified close of 29.05, up 1.36%, dated 12 Aug 2026. It brings the latest available chart,...
Chengdu Olymvax Biopharmaceuticals Inc. Class A (688319) has a latest verified close of 29.05, up 1.36%, dated 12 Aug 2026. It brings the latest available chart, company context, cited sources, risks and the route into the full Atlas research file together. Atlas files 688319 under Healthcare & Medicine Stocks for browsing.
How often is the 688319 page updated?The 688319 public file is refreshed when a newer verified market bar, company filing, official release or material source update is available. The visible date shows...
The 688319 public file is refreshed when a newer verified market bar, company filing, official release or material source update is available. The visible date shows the freshness of the current market snapshot.
Which sources does Atlas use for 688319?The 688319 file starts with SSE symbol identity and TradingView SSE:688319. The page separates verified market context from company evidence and shows open evidence...
The 688319 file starts with SSE symbol identity and TradingView SSE:688319. The page separates verified market context from company evidence and shows open evidence gaps instead of filling them with assumptions.
Can Atlas run a full research brief on 688319?Yes. The workstation can open a research path for 688319 from the public symbol record and then pull the available public sources for the fuller report.
Yes. The workstation can open a research path for 688319 from the public symbol record and then pull the available public sources for the fuller report.
Is this 688319 page investment advice?No. The 688319 page is a research and source-navigation page. It does not provide personalised financial advice, brokerage execution, a trading instruction, or a...
No. The 688319 page is a research and source-navigation page. It does not provide personalised financial advice, brokerage execution, a trading instruction, or a promise of returns.
Methodology
This profile is generated daily from public sources including SEC EDGAR (US-listed companies), NASDAQ Trader files, exchange listings, public macro/central-bank releases, CoinGecko crypto market files where relevant, and the TradingView global symbol catalog. Multi-model AI may assist drafting and review where configured, but sources remain the evidence rail; the chart is an Atlas static OHLC rail with a live TradingView link when verified bars are available; otherwise the page keeps the verified TradingView route as an explicit fallback.
Research only. Not investment advice. No brokerage execution. No guaranteed returns are promised or implied. FreedomCore does not provide personalised investment advice. Always consult a regulated financial advisor before making investment decisions.
Profile last updated: 2026-07-30. Browse FreedomCore Atlas research notes →